RCM Capital Advisors Healthcare Funding Advisory

RCM Capital Advisors · Toronto · Established 1993

Families funding healthcare are well advised on structure.
Far less well advised on substance.

We help families, family offices and foundations decide what to fund, whom to fund, how much to commit and when — then verify, on the family's behalf, that the money is producing the outcome it was intended to produce.

Begin a conversation See how an engagement works
30+Years in complex
case navigation
4,000+Specialists in
referral network
50+Global centres
of excellence
5Senior advisors in
the consulting group

The proposition in one sentence

We bring healthcare content expertise to the one table where it is almost always missing — the table where a family decides where its capital will go.

Healthcare is not a single market. It is a layered ecosystem of clinicians, hospitals, universities, regulators, payers, procurement bodies, manufacturers, distributors, data systems and patient communities — each with its own incentives, timelines and definitions of success.

A gift that would transform one part of that system can be quietly absorbed and disappear in another. Telling the difference is a research discipline, not an instinct.

Read why this practice exists →

What we bring

Thirty years inside the system, now applied to capital

Ground truth

We have referred real patients to real programs

Reputation and performance are correlated but not identical. Three decades of active referral produces a candid view of who actually executes.

Independence

We are paid by the family and nobody else

We do not solicit funding for, hold interests in, or accept compensation from the organisations we evaluate.

Verification

We return after the money is committed

Milestone review and burn-rate audit, so the family is never dependent solely on the recipient's own reporting.

Where personal motivation meets rigour

The anchor is often a person

One family we have worked with lost a child to a rare brain tumour, and went on to raise substantial funding toward a cure. That personal anchor is a strength — it sustains commitment across decades.

It is best served, not diminished, by rigorous analysis of where the money will do the most good.

Next

Why this practice exists →
Begin a conversation
02 / 08

Why this practice exists

The problem is not a shortage of worthy causes

It is a shortage of the analytic capability required to distinguish between them.

Families who choose to direct capital into healthcare are making one of the most consequential decisions available to private wealth. They are also making one of the hardest.

Most families making these decisions are well advised on structure and less well served on substance. Their lawyers and accountants are expert in governance, tax treatment, trust and foundation architecture, and fiduciary duty — expertise that is essential.

But healthcare content expertise sits outside that remit. Nobody at the table is positioned to answer the questions that actually determine outcome.

Four gaps recur

Every family we speak with recognises at least two of them, usually after a commitment has already been made. Naming them early is most of the remedy.

Gap one

The advisory gap

Trusted advisors are expert in structure, tax and governance — not in clinical evidence, translational science, regulatory pathways or health system economics. The family is well advised on form, unadvised on substance.

Gap two

The evidence gap

Funding proposals are written to persuade. They rarely disclose competing approaches, realistic timelines, prior failed attempts or the risk that the science does not replicate — and nobody on the family's side can stress-test them.

Gap three

The scale gap

Many initiatives can show a successful pilot. Far fewer have a credible path from one site to twenty, or from a research finding to a funded standard of care. The distance between proof and adoption is where most healthcare philanthropy stalls.

Gap four

The feedback gap

Once funds are committed, families receive narrative reports from the recipient — rarely an independent assessment of burn rate, milestone achievement, or whether the original thesis still holds.

We close all four gaps with the same discipline we have always applied for individual patients: independent verification, direct access to the people who actually know, and a refusal to accept a claim simply because it is confidently presented.

Next

Our vantage point →
What we do
03 / 08

Our vantage point

Not the view from a boardroom or a grant committee

The view from inside the delivery of care itself — thirty years of it, almost always after the standard pathway has failed the patient.

Since 1993, RCM Health Consultancy has served as a concierge healthcare navigation and complex case management firm for high-net-worth individuals, families and corporate clients in Canada and internationally.

Our team of nurses, nurse practitioners, medical case managers and consulting physicians works within a network of more than 4,000 specialists and over 50 international Centres of Excellence — across oncology, rare disease, neurosurgery, cardiology, endocrinology, paediatrics and complex surgical reconstruction, frequently across borders.

RCM Capital Advisors is the funding advisory practice built on that work.

Why it matters to a funding decision

A network built by referring real patients tells you something a directory cannot: which clinicians their own peers regard as excellent, and which programs quietly fail the people they were built for.

What that vantage point teaches

Four things you learn only from inside

  • Where failure sits
    Failure is rarely where press coverage suggests It is usually in coordination, diagnostic delay, and the handoffs between institutions — which is also where new capacity creates disproportionate value.
  • Who delivers
    Reputation and performance are correlated, not identical Thirty years of referring real patients to real programs produces a candid view of who executes and who presents well.
  • Where cash burns
    Good intentions consume years of funding We have watched well-intentioned programs spend heavily while producing conference presentations rather than treated patients.
  • What endures
    Programs survive when a budget absorbs them Endurance comes from absorption into a payer or institutional budget — not from indefinitely renewed philanthropy. Designing for that absorption is a discipline, not an accident.
1993Year the practice
was founded
4,000+Specialists reachable
directly
50+International centres
of excellence
8Clinical domains
routinely navigated

Next

What we do →
Meet the consulting group
04 / 08

What we do

An independent advisor to the family, and to nobody else

We have assembled a consulting group of five very senior healthcare advisors to work alongside families, family offices and foundations on funding decisions.

The group is deliberately constructed to cover the full arc of a healthcare initiative — underlying science, clinical validity, regulatory and intellectual property strategy, commercial and operating model, data infrastructure, and finally payer adoption and system integration.

Advisors are assigned to each mandate according to its subject matter, and the family meets the advisors who will do the work before the work begins.

We decide what to fund, whom to fund, how much to commit and when to commit it — then verify that the money is producing the outcome it was intended to produce.

Position

What we are, and what we are not

Independent

We work for the family

We do not solicit funding for, hold interests in, or accept compensation from the organisations we evaluate. Our only client is the family.

Complementary

Content experts, not structure experts

We work alongside the family's legal and accounting advisors, providing the healthcare substance their structuring work requires.

Operating

Practitioners, not observers

Every member of the group has built, operated, funded or scaled something in healthcare — and carries the scars that go with it.

Who we work with

Families, family offices and foundations

In Canada and globally, whether the commitment is a first significant gift or a multi-decade programme already under way.

  • Families with a personal anchor — a diagnosis, a loss, or a conviction that has shaped where the capital should go.
  • Family offices carrying responsibility for healthcare allocations without in-house clinical or scientific capability.
  • Private foundations and trustees requiring documented, defensible diligence for the record.
  • Rising generations inheriting both wealth and philanthropic intent, with their own convictions about what healthcare should be.

Next

The consulting group →
The process
05 / 08

The consulting group

Five advisors, presented by capability

So that families can assess the collective range of the group. Full biographies are provided under confidentiality once an engagement discussion begins.

I

Clinical navigation
System access
Complex case management

Physician-led practice leadership, three decades inside the system on behalf of the most difficult diagnoses

  • Direct working relationships across 4,000+ specialists and 50+ international Centres of Excellence, built through active patient referral rather than directory compilation.
  • Second-opinion facilitation, cross-border care coordination and clinical case navigation across oncology, endocrine, neurosurgical, rare disease and complex surgical presentations.
  • Design and operation of corporate health programs, health spending structures and nurse practitioner service models.

Brings to a funding decisionGround truth — whether a program actually helps patients, and whether the clinicians behind it are regarded by their peers as excellent.

II

Corporate strategy
Business development
M&A and intellectual property

Doctorate in virology and neuroscience, MBA in corporate strategy, registered US patent agent

  • Executive director of global strategy, innovation and alliances at a top-tier global pharmaceutical company; led corporate strategy, business cases, acquisition targeting and global partnering structures including consortiums and public–private partnerships.
  • Led due diligence across scientific, clinical, regulatory, intellectual property, legal, financial, commercial and manufacturing dimensions for in-licensing and M&A transactions.
  • Twice a founder and chief executive — licensing a first-in-class asset from a research institution, recruiting a C-suite, building development plans and raising capital including non-dilutive financing.
  • Former equity research analyst covering biotechnology and pharmaceuticals; graduate lecturer in biotechnology commercialisation and healthcare start-up formation at three universities.

Brings to a funding decisionTransaction discipline — the ability to value an asset, test the deal terms, and assess whether the intellectual property will hold.

III

Translational science
Platform due diligence
AI in discovery

Doctorate in pharmaceutical sciences, founding scientist and diligence lead for venture groups in the US and UK

  • Founding scientist — second employee — at a venture-created biotechnology company within a leading life sciences innovation foundry; co-developed two platform technologies from proof of concept through primate-ready material on a program budget exceeding US$5 million.
  • Leads scientific due diligence, platform feasibility assessment and go/no-go analysis across drug delivery, RNA therapeutics, gene therapy, immuno-oncology, rare disease and AI-driven discovery.
  • Co-inventor of a granted patent that led to the formation of a spin-out company; 30+ peer-reviewed publications, 10+ as first author, in leading nanomedicine and controlled-release journals.
  • Active focus on how artificial intelligence is reshaping target identification, discovery and platform development — increasingly relevant to any research funding decision made today.

Brings to a funding decisionScientific candour — whether the underlying science is real, differentiated, and likely to survive contact with development.

IV

Commercial leadership
Scale-up and brand
Governance

MBA and certified corporate director, with global operating accountability across devices, diagnostics and digital health

  • Global business unit head reporting to the chief executive, with full strategic and financial accountability for a connected medical device and software portfolio of roughly €600 million in annual sales across 45+ country markets; executive management board member.
  • Regional head across North and Latin America and country general manager in Canada, with full profit-and-loss responsibility for organisations of 100+ employees and sustained double-digit growth.
  • Led product development from ideation through commercial launch, including a behavioural-health software application supported by two completed clinical trials, and payer contracting in the United States.
  • Board and advisory work with digital health start-ups and investment and research firms; formal training in corporate governance and directorship.

Brings to a funding decisionExecution realism — whether a team can move from pilot to market, and whether the governance around the money is adequate.

V

Health data
Artificial intelligence
Payer systems and operations

Clinical pharmacist with an MBA in biotechnology and twenty-five years across insurers, providers and government health programs

  • Directed a specialty pharmacy payer solutions business with a $250 million profit-and-loss and a team of 35+ across case management, analytics, product and clinical; delivered 40% year-over-year revenue growth alongside 96% patient satisfaction.
  • Senior manager of data and AI strategy at a global professional services firm; led implementation of an AI-enabled commercial platform and multi-year digital transformation roadmaps.
  • Director of group health solutions at a major Canadian insurer, with responsibility for drug, dental and wellbeing portfolio strategy — a direct line of sight into what payers will and will not ultimately fund.
  • Provincial drug eHealth strategy work and the first electronic prescribing implementation in Ontario, adopted across two communities and 42 regional pharmacies.

Brings to a funding decisionAdoption reality — whether the initiative can be measured, integrated into existing systems, and eventually paid for by someone other than the family.

A note on anonymity

Advisors are presented by capability so the group can be assessed as a whole rather than as a set of résumés. Identities and full biographies are disclosed under confidentiality at the appropriate stage of an engagement — and the family always meets the advisors assigned to its mandate before work begins.

Next

The process →
Begin a conversation
06 / 08

The process

Ten stages, each with a decision point

Every stage has a discrete deliverable and a moment at which the family may proceed, pause or stop. No stage obliges the family to enter the next.

01
Preliminary discussion

An exploratory conversation about the family's intent, values, time horizon and existing commitments. No obligation — the purpose is to establish fit.

02
Charter and work plan

The family's narrative becomes a written charter: objectives, the definition of success to be used, geographic and thematic scope, governance and reporting expectations, and an indicative funding envelope. A costed research work plan follows.

03
Landscape and target identification

Structured research across the chosen field: who is working on the problem, what has been tried, where the genuine gaps sit, and which organisations, programs or investigators merit closer examination. Delivered as a shortlist with written inclusion and exclusion rationale.

04
Due diligence

Deep evaluation of selected targets: scientific and clinical validity, team capability, intellectual property, regulatory pathway, competitive landscape, financial condition, governance, existing funders and reputational risk — including reference calls with clinicians and operators who know the target directly.

05
Quantum and timing analysis

We run the numbers. What level of funding produces what outcome, over what period? Where does the marginal dollar stop producing marginal impact? We model tranche structures, milestone triggers and the consequences of funding too little, too much or too early.

06
Sustainability and scalability assessment

What is required for the initiative to continue and expand: personnel, infrastructure, partners, and the private and public funding that must eventually replace the family's contribution — delivered as a scale pathway with named prerequisites and constraints.

07
Recommendation report

A written report setting out findings, recommended targets, recommended quantum and timing, proposed conditions and milestones, and the risks the family should accept knowingly. Presented in person and, where wished, to the family's legal and accounting advisors.

08
Post-funding review and burn-rate audit

We return to review progress against the milestones set at the outset and audit the cash burn rate, reporting whether the original thesis still holds and whether continuation, restructuring or discontinuation is warranted.

09
Co-funding and syndication

Where the family wishes to extend impact beyond its own commitment, we identify and approach other families, family offices and foundations whose priorities align, and support the formation of a co-funding group.

10
Lessons learned

With express permission and all private details withheld, we publish what the funding achieved and what it taught — anonymously where preferred — contributing to a shared evidence base for families funding healthcare.

How mandates are scoped

Stage by stage, or as a continuing programme

Engagements are typically structured as fixed-fee work plans by stage, or as a retainer where the family expects a continuing programme of funding decisions over several years.

The preliminary discussion carries no commitment.

Next

How we evaluate →
Begin a conversation
07 / 08

How we evaluate

Three lenses. A target must hold up under all of them.

An initiative that performs on only one lens is not, in our view, a sound recipient of significant family capital.

Social impact
Who is measurably better off, by how much, and how would we know?

Beneficiary population and its size; the outcome measure and its credibility; the baseline against which change is assessed; attribution — whether the change would have occurred anyway; equity of access; and the lag between funding and observable benefit.

Sustainability
What happens when the family's money stops?

Path to institutional, payer or public funding absorption; operating cost structure and trajectory; dependence on named individuals; governance and succession; revenue diversity; and whether the program survives a leadership change.

Scalability
Can this serve ten or a hundred times more patients?

Whether the model is replicable or artisanal; unit economics as volume rises; infrastructure, data and workforce prerequisites; regulatory and licensing constraints across jurisdictions; partner availability; and the bottleneck that binds first.

What the family receives

Documents, access and continuity

Documents

A written charter; a shortlist memorandum with inclusion and exclusion rationale; due diligence reports on each target; a quantum and timing model; a scale pathway assessment; and a final recommendation report — each to a standard the family's advisors can rely upon.

Access and continuity

Direct access to the assigned advisors; introductions to clinicians, institutions and operators; presentation of findings to the family and the next generation; and ongoing monitoring, so the family is never dependent solely on the recipient's own reporting.

For the family's legal and accounting advisors

Findings that translate into agreements

This practice sits alongside, not in place of, the family's existing professional advisors. Our work is prepared to drop directly into grant agreements, disbursement schedules, reporting covenants and foundation minutes.

  • Milestone-conditioned disbursement. Our quantum and timing analysis produces tranche triggers counsel can draft into funding agreements, giving recourse if performance does not materialise.
  • Independent verification for the record. Post-funding burn-rate audits and progress reviews give trustees and directors an evidentiary basis for their oversight obligations.
  • Documented decision rationale. Written inclusion and exclusion reasoning demonstrates prudent process — increasingly important to boards, trustees and the next generation.

Next

Begin a conversation →
The consulting group
08 / 08

Begin a conversation

The first conversation commits you to nothing

We welcome inquiries from families, family offices and foundations interested in how our consulting group can support their efforts to improve the healthcare system and help more patients gain timely access to high-quality care.

Raymond Rupert, MD, MBA

Principal Consultant · RCM Health Consultancy Inc.

Cell416 543 6514
Emailrrupert@rcmhealth.ca
OfficeToronto, Canada
Since1993

A note to the next generation

Many families we work with are transferring both wealth and philanthropic intent to a rising generation with its own convictions about what healthcare should be. We welcome that generation from the first conversation.

Funding decisions made jointly across generations are better decisions — and far more durable ones.

Request a preliminary discussion

Tell us a little about your intent. We will respond within two business days to arrange a confidential conversation.

Submissions are treated as confidential. We do not share inquiries with any third party, and we do not accept compensation from the organisations we evaluate.

Mandates are scoped stage by stage. The family meets the advisors who will do the work before the work begins.